[HTML][HTML] Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants
Imidazoquinoline derivatives (IMDs) and related compounds function as synthetic agonists
of Toll-like receptors 7 and 8 (TLR7/8) and one is FDA approved for topical antiviral and skin …
of Toll-like receptors 7 and 8 (TLR7/8) and one is FDA approved for topical antiviral and skin …
Chemical strategies to boost cancer vaccines
WH Li, YM Li - Chemical reviews, 2020 - ACS Publications
Personalized cancer vaccines (PCVs) are reinvigorating vaccine strategies in cancer
immunotherapy. In contrast to adoptive T-cell therapy and checkpoint blockade, the PCV …
immunotherapy. In contrast to adoptive T-cell therapy and checkpoint blockade, the PCV …
Toll-like receptor 9 agonists in cancer
L Karapetyan, JJ Luke, D Davar - OncoTargets and therapy, 2020 - Taylor & Francis
Abstract Toll-like receptor 9 (TLR9) is a pattern recognition receptor that is predominantly
located intracellularly in immune cells, including dendritic cells, macrophages, natural killer …
located intracellularly in immune cells, including dendritic cells, macrophages, natural killer …
Inhibition of RNA-binding proteins with small molecules
P Wu - Nature Reviews Chemistry, 2020 - nature.com
Protein–RNA interactions have crucial roles in various cellular activities, which, when
dysregulated, can lead to a range of human diseases. The identification of small molecules …
dysregulated, can lead to a range of human diseases. The identification of small molecules …
Structural and functional understanding of the toll‐like receptors
J Asami, T Shimizu - Protein Science, 2021 - Wiley Online Library
Recognition of invading pathogens by the innate immune system is essential to initiate
antimicrobial responses and trigger adaptive immunity. This is largely mediated by an array …
antimicrobial responses and trigger adaptive immunity. This is largely mediated by an array …
Small-molecule modulators targeting toll-like receptors for potential anticancer therapeutics
J Wang, J Zhang, J Wang, X Hu… - Journal of Medicinal …, 2023 - ACS Publications
Toll-like receptors (TLRs) are key components of the innate immune system and serve as a
crucial link between innate and acquired immunity. In addition to immune function, TLRs are …
crucial link between innate and acquired immunity. In addition to immune function, TLRs are …
Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes
C Patinote, NB Karroum, G Moarbess, N Cirnat… - European journal of …, 2020 - Elsevier
The discovery of the TLRs family and more precisely its functions opened a variety of gates
to modulate immunological host responses. TLRs 7/8 are located in the endosomal …
to modulate immunological host responses. TLRs 7/8 are located in the endosomal …
[HTML][HTML] TLR7 and TLR8 differentially activate the IRF and NF-κB pathways in specific cell types to promote inflammation
AT Bender, E Tzvetkov, A Pereira, Y Wu, S Kasar… - …, 2020 - journals.aai.org
TLR7 and TLR8 are pattern recognition receptors that reside in the endosome and are
activated by ssRNA molecules. TLR7 and TLR8 are normally part of the antiviral defense …
activated by ssRNA molecules. TLR7 and TLR8 are normally part of the antiviral defense …
[HTML][HTML] Development of adamantane-conjugated TLR7/8 agonists for supramolecular delivery and cancer immunotherapy
Tumor-associated macrophages (TAMs) are often abundant in solid cancers, assuming an
immunosuppressive (M2-like) phenotype which supports tumor growth and immune escape …
immunosuppressive (M2-like) phenotype which supports tumor growth and immune escape …
Lipid Trolling to Optimize A3 Adenosine Receptor-Positive Allosteric Modulators (PAMs)
A3 adenosine receptor (A3AR) positive allosteric modulators (PAMs)(2, 4-disubstituted-1 H-
imidazo [4, 5-c] quinolin-4-amines) allosterically increase the E max of A3AR agonists, but …
imidazo [4, 5-c] quinolin-4-amines) allosterically increase the E max of A3AR agonists, but …